---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000077"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:22:50.166370+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics addresses FAERS report of retinal tear in VIZZ patient with pre-existing risk factors

## Summary
- FAERS report describes retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44%.
- Patient had significant retinal pathology history: lattice degeneration, prior laser, previous tear; no recent peripheral exam.
- Independent retina specialists note multiple pre-existing risk factors making spontaneous retinal events more likely.
- Company states this initial report does not alter current safety expectations for VIZZ.

## SEC filing metadata
- accession: 0001815776-25-000077
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000077/0001815776-25-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000077/lenz-20251212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000077
- JSON: https://secwatch.observer/filing/0001815776-25-000077.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.